Peptide Glossary

The building blocks of peptides and proteins. There are 20 standard amino acids that combine in various sequences to form peptides.

A modified version of a naturally occurring peptide, engineered to improve stability, bioavailability, potency, or half-life. Semaglutide is an analogue of GLP-1.

The attachment of a fatty acid chain to a peptide, enabling it to bind albumin in the bloodstream and dramatically extending its half-life. Semaglutide and cagrilintide use this strategy.

A measured portion of a solution divided from a larger volume. Peptides may be aliquoted into single-use portions to avoid repeated freeze-thaw cycles.

A peptide hormone co-secreted with insulin by pancreatic beta cells. It slows gastric emptying, suppresses glucagon secretion, and promotes satiety. Pramlintide is a synthetic amylin analogue; cagrilintide is a long-acting acylated amylin analogue used for weight management.

The formation of new blood vessels from existing ones. Some peptides like BPC-157 are studied for their potential to promote angiogenesis in healing.

A cellular energy sensor activated when ATP levels are low (e.g., during exercise or fasting). AMPK activation promotes glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and autophagy. AICAR (a nucleoside analog, not a peptide) activates AMPK indirectly via its intracellular metabolite ZMP; the mitochondrial-derived peptide MOTS-c also activates AMPK signaling.

A cellular recycling process where damaged proteins and organelles are engulfed and degraded. Important for cellular maintenance and longevity. Fasting, AMPK activation, and certain peptides may promote autophagy.

Programmed cell death — a controlled process by which damaged or unnecessary cells self-destruct. Senolytic peptides like FOXO4-DRI work by re-enabling apoptosis in senescent cells that have become resistant to it.

A quality control test that determines the amino acid composition and quantity of a peptide sample. Used alongside HPLC and mass spectrometry on COAs to verify peptide identity.

Any undesirable experience associated with the use of a medical product, whether or not considered related to the product. Serious adverse events include hospitalization, disability, or life-threatening outcomes.

A severe, potentially life-threatening allergic reaction that can occur within seconds or minutes of exposure. Although rare with peptides, it requires immediate medical attention (epinephrine, emergency services).

Antibodies produced by the immune system against a therapeutic peptide or protein. ADA formation can neutralize the drug's effect or cause adverse immune reactions. Monitored in clinical trials of biologic therapies.

The clumping together of peptide molecules, often caused by heat, agitation, or repeated freeze-thaw cycles. Aggregated peptides may lose potency and can trigger immune reactions if injected.

Short peptides (typically 2-4 amino acids) developed primarily in Russian research, theorized to support specific organ systems. Examples include Cartalax (cartilage), Livagen (liver), and Pinealon (brain). Clinical evidence is limited to Russian-language publications.

Sterile water containing 0.9% benzyl alcohol as a preservative. Used to reconstitute lyophilized peptides. Unlike sterile water, it inhibits bacterial growth and allows multi-dose use.

The proportion of a substance that enters the circulation when introduced into the body and is able to have an active effect. Different administration routes affect bioavailability.

A protein that supports neuron survival, growth, and synaptic plasticity. Critical for learning and memory. Several nootropic peptides (Semax, Selank, Cerebrolysin, Dihexa) are studied for their ability to increase BDNF expression.

A selective permeability barrier formed by tightly joined endothelial cells lining brain capillaries. Prevents most peptides from reaching brain tissue. Intranasal delivery, lipophilic modifications, or small peptide size can help bypass the BBB.

An active pharmaceutical ingredient (API) used as a starting material in compounding. The FDA maintains lists of bulk drug substances that may or may not be used by 503A and 503B compounding entities.

The FDA's most serious warning placed on a drug's prescribing information, indicating significant risks of serious or life-threatening adverse effects. GLP-1 agonists carry a black box warning for thyroid C-cell tumors based on rodent studies.

A measurable biological indicator used to assess normal processes, disease states, or responses to treatment. IGF-1 levels are a common biomarker for growth hormone secretagogue therapy.

The date after which a compounded preparation should not be used. Determined by the compounding pharmacy based on stability data. Differs from expiration date, which applies to manufactured drugs.

A chemical modification that joins the ends of a peptide chain into a ring, improving stability and resistance to enzymatic breakdown. Many therapeutic peptides use cyclization to extend their half-life.

The temperature-controlled supply chain required for storing and shipping certain peptides. Lyophilized peptides are typically stored at -20°C; reconstituted peptides at 2-8°C. Cold chain failures during shipping have led to FDA recalls.

A transcription factor activated by cAMP signaling that plays a key role in memory formation, neuronal survival, and neuroplasticity. Nootropic peptides like Semax and Dihexa are studied for their effects on CREB-dependent gene expression.

A phospholipid found almost exclusively in the inner mitochondrial membrane, essential for the function of respiratory chain complexes and ATP production. Cardiolipin damage is linked to aging and metabolic disease. The peptide SS-31 (Elamipretide) selectively binds cardiolipin to stabilize mitochondrial function.

The inward folds of the inner mitochondrial membrane where the electron transport chain and ATP synthase are located. Cristae structure determines mitochondrial efficiency. Cardiolipin stabilization by SS-31 helps maintain normal cristae architecture.

A document from a laboratory (ideally third-party) that certifies the identity, purity, potency, and quality of a substance. Essential for verifying research peptide quality.

FDA regulations that ensure pharmaceutical products are consistently produced and controlled according to quality standards. Applies to licensed drug manufacturers, not research-grade suppliers.

A unique numerical identifier assigned by the Chemical Abstracts Service to every chemical substance. Each peptide has a specific CAS number (e.g., BPC-157: 137525-51-0) that allows unambiguous identification regardless of naming conventions.

A medication prepared by a licensed compounding pharmacy to meet an individual patient's specific needs. Subject to different regulations than manufactured drugs.

An FDA product recall classification indicating a situation where use of or exposure to the product may cause temporary or medically reversible adverse health consequences. All peptide-related FDA recalls to date have been Class II.

A condition or factor that makes a particular treatment or procedure inadvisable. Absolute contraindications mean the treatment should never be used; relative contraindications mean the benefits may outweigh risks in some cases.

A peptide design strategy where the amino acid sequence is reversed and D-amino acids replace L-amino acids. This preserves side-chain topology while dramatically increasing resistance to enzymatic degradation. FOXO4-DRI uses this approach.

A maleimidopropionic acid linker that binds to serum albumin after injection, extending the half-life of peptides like CJC-1295 from minutes to approximately 8 days.

A liquid used to dilute or reconstitute a substance. For peptides, common diluents include bacteriostatic water and sterile saline.

A reduction in receptor response after prolonged or repeated exposure to an agonist. Can lead to reduced effectiveness of some peptides over time.

A decrease in the number or sensitivity of cell receptors in response to prolonged stimulation. Can reduce a peptide's effectiveness over time and is a reason many protocols include off-cycles.

A graph showing the relationship between the dose of a substance and the magnitude of its effect. Important for understanding therapeutic windows — the range between the minimum effective dose and the dose that causes unacceptable side effects.

A chemical compound resulting from the breakdown of a peptide through oxidation, deamidation, hydrolysis, or other processes. COAs report the percentage of degradation products to indicate product integrity.

An FDA designation that a drug is in shortage, which temporarily allows compounding pharmacies to produce compounded versions. FDA declared semaglutide shortage resolved in February 2025 and tirzepatide in October 2024, restricting further compounding.

A change in the effect of a drug when taken with another drug, supplement, or food. Peptide interactions can be pharmacokinetic (affecting absorption/metabolism) or pharmacodynamic (additive/opposing effects).

A common peptide degradation reaction where asparagine or glutamine residues lose an amide group. Accelerated by heat and alkaline pH. Detected on COAs as impurity peaks.

A moisture-absorbing substance (typically silica gel) included in peptide packaging to prevent humidity-driven degradation during storage of lyophilized powders.

An inactive substance that serves as a carrier or stabilizer in a formulation. Mannitol is a common excipient in lyophilized peptide products.

A polymer coating on oral capsules or tablets designed to resist stomach acid and dissolve in the alkaline environment of the small intestine. Used for oral peptide formulations like oral BPC-157 to protect peptides from gastric degradation.

Toxic substances (lipopolysaccharides) released from the cell walls of gram-negative bacteria. Endotoxin testing (LAL test) is important for injectable peptide quality.

The EU regulatory agency responsible for evaluating and supervising medicines. Equivalent to the FDA in the United States. Peptide regulations differ between EMA and FDA jurisdictions.

A specific, measurable outcome in a clinical trial used to evaluate whether a treatment works. Primary endpoints are the main outcomes; secondary endpoints provide additional evidence.

The phenomenon where a drug is metabolized by the liver before reaching systemic circulation, significantly reducing bioavailability. This is a primary reason most peptides are administered by injection rather than orally.

Under FDA compounding rules, a substance placed on the Category 2 list is nominated for evaluation but has not yet been approved for use in compounding by 503A or 503B pharmacies. BPC-157 has been placed on this list.

Under FDA compounding rules, substances on the Category 1 list have been evaluated and approved as bulk drug substances eligible for compounding by 503A and 503B pharmacies.

A cycle of freezing and thawing a substance, which can damage peptide structure through ice crystal formation and aggregation. Multiple freeze-thaw cycles significantly degrade peptides; aliquoting prevents this.

An incretin hormone that stimulates insulin secretion, inhibits glucagon release, slows gastric emptying, and reduces appetite. GLP-1 receptor agonists like semaglutide mimic this hormone.

An incretin hormone that, like GLP-1, stimulates insulin secretion. Tirzepatide is a dual GLP-1/GIP agonist, and retatrutide is a triple GLP-1/GIP/glucagon agonist.

A peptide hormone produced by the alpha cells of the pancreas that raises blood glucose levels by stimulating glycogenolysis and gluconeogenesis. Also increases energy expenditure. Dual GLP-1/glucagon agonists like survodutide combine appetite suppression with metabolic activation.

A peptide hormone produced primarily in the stomach that stimulates appetite, growth hormone release, and fat storage. Known as the "hunger hormone." Growth hormone secretagogues like GHRP-6 and MK-677 act on the ghrelin receptor (GHS-R1a).

A substance that stimulates the pituitary gland to produce and release growth hormone. Examples include ipamorelin, GHRP-6, and MK-677.

A class of synthetic peptides that stimulate growth hormone release by activating the ghrelin receptor (GHS-R1a). Includes GHRP-2, GHRP-6, hexarelin, and ipamorelin. Each variant has different potency and side-effect profiles regarding hunger, cortisol, and prolactin.

A hypothalamic hormone that stimulates growth hormone synthesis and release from the pituitary. Sermorelin, tesamorelin, and CJC-1295 are synthetic GHRH analogues. GHRH peptides are often stacked with GHRPs for synergistic GH release.

The ghrelin receptor, a G protein-coupled receptor primarily expressed in the pituitary and hypothalamus. Activation by ghrelin or synthetic GHRPs stimulates growth hormone release, appetite, and reward signaling. Also known as the ghrelin receptor.

Delayed gastric emptying causing nausea, vomiting, and early satiety. A recognized side effect of GLP-1 receptor agonists due to their mechanism of slowing gastric motility.

Conditions affecting the gallbladder including gallstones and cholecystitis. Rapid weight loss from GLP-1 agonists increases gallstone risk; patients should report right upper quadrant pain.

The time required for the concentration of a substance in the body to decrease by half. Determines dosing frequency and accumulation patterns.

An analytical technique used to separate, identify, and quantify components in a mixture. Used in COAs to determine peptide purity percentage.

An injection administered directly into a muscle. Some peptides may be administered via IM injection under medical supervision.

Administration directly into a vein. Provides 100% bioavailability but requires medical supervision and sterile technique.

Administration through the nasal mucosa. Some peptides (Semax, Selank, oxytocin) are administered intranasally to bypass GI degradation and potentially access the blood-brain barrier more directly.

A syringe calibrated in units (typically 100 units per mL) designed for precise measurement of small volumes. Commonly used for peptide administration.

The practice of alternating injection locations (abdomen, thighs, upper arms) to prevent lipohypertrophy, scar tissue formation, and ensure consistent absorption.

A non-invasive route of peptide administration via nasal spray. Allows some peptides to bypass the blood-brain barrier through the olfactory epithelium. Bioavailability varies widely (2-30%) depending on the peptide and formulation.

A gut hormone released after eating that enhances insulin secretion in a glucose-dependent manner. GLP-1 and GIP are the two main incretins. Incretin-based peptide therapies (semaglutide, tirzepatide) exploit this pathway for diabetes and weight management.

International Nomenclature of Cosmetic Ingredients — the standardized naming system required on cosmetic product labels worldwide. Relevant for topical peptide products like GHK-Cu (INCI: Copper Tripeptide-1) and Matrixyl (INCI: Palmitoyl Pentapeptide-4).

An FDA application that allows an experimental drug or peptide to be used in clinical trials on humans. Most research peptides have not filed an IND and therefore cannot legally be marketed for human use.

The ability of a substance to provoke an immune response. Some peptides can trigger anti-drug antibody formation over time, potentially reducing efficacy or causing allergic reactions.

A localized adverse response at the injection location, ranging from mild redness and swelling to nodules or infections. Proper technique and site rotation minimize risk.

Experiments performed in a controlled environment outside a living organism, such as in cell cultures or test tubes. "In vitro only" evidence is insufficient to draw conclusions about effects in humans.

Experiments performed in living organisms, including animal models and human subjects. In vivo evidence is stronger than in vitro but animal results do not reliably predict human outcomes.

A signaling pathway used by cytokines, interferons, and growth factors to regulate immune responses, cell growth, and differentiation. Some immunomodulatory peptides interact with JAK/STAT signaling to modulate inflammation.

The freeze-drying process used to convert peptide solutions into stable powders for long-term storage. Removes water under vacuum at low temperature, preserving the peptide's molecular structure. Lyophilized peptides can remain stable for years at -20°C.

Freeze-dried. Peptides are commonly sold in lyophilized (powdered) form to preserve stability during storage. Must be reconstituted before use.

An initial higher dose of a peptide given to rapidly reach therapeutic concentration in the body. Often followed by a lower maintenance dose. Common in protocols for BPC-157 blends and growth hormone secretagogues.

Localized accumulation of fat tissue at injection sites, caused by repeated injections in the same area. Prevented by systematic rotation of injection sites across abdomen, thighs, and upper arms.

A test using horseshoe crab blood extract to detect bacterial endotoxin contamination in injectable products. A passing LAL result on a COA indicates endotoxin levels are below the safety threshold.

A sugar alcohol commonly used as a bulking agent and cryoprotectant in lyophilized peptide formulations. It forms the visible powder cake in the vial and helps protect the peptide during the freeze-drying process.

An emerging delivery technology using tiny needles that painlessly penetrate the skin barrier to deliver peptides. Still largely experimental but may offer a needle-free alternative to subcutaneous injection.

The ongoing dose administered after the loading phase to sustain therapeutic peptide levels. Typically lower than the loading dose and taken over an extended period.

A family of G protein-coupled receptors (MC1R through MC5R) involved in skin pigmentation, sexual function, appetite regulation, and inflammation.

A protein that inhibits muscle growth. Follistatin peptides are studied for their ability to block myostatin, theoretically allowing increased muscle development. Evidence is limited to preclinical studies.

A chain of proteins (Ras-Raf-MEK-ERK) that transmits growth signals from cell surface receptors to the nucleus, promoting cell division and differentiation. Relevant to tissue-repair peptides like BPC-157 and growth factors like IGF-1.

The process by which cells increase their number of mitochondria, enhancing energy production capacity. Stimulated by exercise, AMPK activation, and studied peptides like MOTS-c and AICAR.

An analytical technique that measures the mass-to-charge ratio of molecules. Used in COAs to confirm peptide identity and molecular weight.

The UK regulatory body responsible for ensuring medicines and medical devices are safe. Classifies most therapeutic peptides as prescription-only medicines (POM).

The FDA's safety information and adverse event reporting program. Healthcare professionals and consumers can report adverse events from peptide medications through MedWatch.

A statistical technique that combines results from multiple studies to produce a single estimate of effect. Provides the strongest form of evidence when based on high-quality RCTs.

A peptide that acts as a neurotransmitter or neuromodulator in the nervous system. Examples include Semax and Selank, which are approved in Russia for cognitive and anxiolytic effects respectively.

A protein complex that controls transcription of inflammatory genes. When activated, NF-κB drives production of pro-inflammatory cytokines. Several peptides (KPV, BPC-157, Thymosin Alpha-1) are studied for their ability to inhibit NF-κB, reducing inflammation.

The use of an FDA-approved drug for a purpose, population, or dosage other than what was approved. Many peptides prescribed by physicians are used off-label based on emerging research.

A pharmaceutical developed to treat a rare disease affecting fewer than 200,000 people in the US. Orphan Drug designation provides tax credits and market exclusivity incentives. Some peptides receive orphan status for rare conditions.

A study where researchers observe outcomes without intervening or assigning treatments. Provides weaker evidence than RCTs due to potential confounding factors, but useful for studying long-term safety.

A degradation reaction where methionine, cysteine, or tryptophan residues in peptides react with oxygen. Exposure to light, air, or peroxides accelerates oxidation. Causes loss of potency.

A short chain of amino acids (typically 2-50 amino acids) linked by peptide bonds. Shorter than proteins but with diverse biological activities.

The chemical bond formed between two amino acids when the carboxyl group of one reacts with the amino group of another, releasing water.

The attachment of polyethylene glycol (PEG) chains to a peptide, increasing its molecular size, reducing kidney clearance, and extending its half-life. PEG-MGF is an example.

A single vial containing two or more peptides pre-mixed by the supplier. Differs from a stack where each peptide is in its own vial. Common blends include BPC-157 + TB-500 and CJC-1295 + Ipamorelin.

The practice of using two or more peptides concurrently, often targeting complementary mechanisms of action. Common stacks include BPC-157 + TB-500 for tissue repair and CJC-1295 + Ipamorelin for growth hormone release. Most stacking protocols lack clinical validation.

The study of how a drug moves through the body — absorption, distribution, metabolism, and excretion (ADME).

The study of what a drug does to the body — its mechanism of action, therapeutic effects, and dose-response relationships. Complementary to pharmacokinetics.

A proton-coupled peptide transporter (SLC15A1) in the intestinal epithelium that absorbs di- and tripeptides from digested food. It is the primary mechanism by which short oral peptides and bioregulators may achieve systemic absorption. Larger peptides cannot use this transporter.

A central intracellular signaling cascade that regulates cell growth, metabolism, survival, and protein synthesis. Activated by growth factors including IGF-1 and insulin. Many anabolic and growth-promoting peptides exert effects through this pathway. mTOR inhibition (e.g., by rapamycin) is a separate longevity research strategy.

The percentage of the desired compound in a sample, as opposed to impurities, degradation products, or other contaminants. Research-grade peptides typically claim >98% purity.

An FDA advisory committee that evaluates substances nominated for inclusion on the bulk drug substance lists used in compounding. PCAC reviews safety, efficacy, and historical use data to recommend whether substances should be permitted for compounding under sections 503A and 503B.

Inflammation of the pancreas causing severe abdominal pain. Monitored as a potential adverse event with GLP-1 receptor agonists. Patients are advised to seek immediate medical attention for severe abdominal pain.

The first stage of clinical testing in humans, typically involving 20-100 healthy volunteers. Tests safety, dosage, and side effects. Most peptides in the research pipeline are at or before this stage.

Clinical trials involving 100-300 patients with the target condition. Tests efficacy and further evaluates safety. Provides initial evidence of whether a peptide works for its intended purpose.

Large-scale clinical trials involving 1,000-3,000+ patients. Confirms efficacy, monitors adverse effects, and compares to existing treatments. Required for FDA drug approval.

Research conducted before clinical trials in humans, including in vitro studies and animal models. Many peptide claims are based solely on preclinical data, which has a high failure rate when translated to humans.

An improvement in symptoms that occurs due to the expectation of treatment rather than the treatment itself. Controlled trials use placebos to distinguish real drug effects from expectation-driven improvements.

A statistical measure indicating the probability that observed results occurred by chance. A p-value below 0.05 is conventionally considered statistically significant, but does not indicate clinical significance or effect size.

The tendency for studies with positive results to be published more often than studies with negative or null results. Creates a skewed evidence base that can overestimate peptide efficacy.

The process of adding a solvent (usually bacteriostatic water) to a lyophilized peptide to create a liquid solution for use.

A substance that binds to a receptor and activates it, mimicking the action of a naturally occurring substance. Many therapeutic peptides are receptor agonists.

A substance that binds to a receptor and blocks its activation, preventing the natural ligand from exerting its effect.

A regulatory designation indicating a product is intended solely for laboratory research and is not approved for human consumption or therapeutic use.

An FDA-required safety program for medications with serious safety concerns. Ensures benefits outweigh risks through prescriber certification, patient agreements, or restricted distribution.

A study where participants are randomly assigned to receive either the treatment or a control (placebo or standard care). The gold standard for establishing causality in medical research.

The specific order of amino acids in a peptide chain, typically written using three-letter or one-letter amino acid codes. Determines the peptide's structure and function.

A peptide that functions as a biological messenger, binding to cell receptors to regulate processes such as appetite, fluid balance, and endocrine function. Examples include GLP-1, oxytocin, and kisspeptin.

Water that has been sterilized and contains no preservatives. Unlike bacteriostatic water, it does not inhibit bacterial growth and should be used for single-dose preparations only.

An injection administered into the fatty tissue layer between the skin and muscle. The most common route for peptide self-administration.

Administration under the tongue where the substance is absorbed through the oral mucosa directly into the bloodstream, partially bypassing first-pass metabolism. Some peptides are explored via this route.

A substance that stimulates the secretion of another substance. In peptide contexts, usually refers to growth hormone secretagogues (GHS) that stimulate pituitary GH release.

A substance that selectively eliminates senescent (aged, non-dividing) cells. FOXO4-DRI is an experimental senolytic peptide studied in cell and animal models.

Cells that have permanently stopped dividing but resist normal programmed death (apoptosis). They accumulate with age and secrete inflammatory factors (SASP) that damage surrounding tissue. Senolytic peptides like FOXO4-DRI aim to selectively clear these cells.

The cocktail of pro-inflammatory cytokines, chemokines, growth factors, and proteases secreted by senescent cells. SASP contributes to chronic inflammation, tissue dysfunction, and age-related disease. Clearing SASP-producing cells is the goal of senolytic therapies.

A set of proteins (including SNAP-25, VAMP, and syntaxin) that mediate the fusion of neurotransmitter vesicles with the cell membrane, enabling neurotransmitter release. Botox and the cosmetic peptide SNAP-8 work by inhibiting SNARE complex assembly, reducing muscle contraction.

Muscle stem cells located between the sarcolemma and basement membrane of muscle fibers. They activate in response to muscle damage or mechanical stress to repair and regenerate muscle tissue. MGF (Mechano Growth Factor) is studied for its role in satellite cell activation.

Laboratory testing to confirm that an injectable product is free from viable microorganisms. A key component of COAs for injectable peptides, especially from compounding pharmacies and outsourcing facilities.

A localized collection of fluid at an injection site caused by tissue reaction to the injected substance rather than bacterial infection. Can occur with peptide injections and typically resolves without antibiotics.

A comprehensive summary of all available research on a specific question, using predefined criteria to identify, evaluate, and synthesize studies. Higher evidence quality than individual studies.

A peptide formulated for application directly to the skin, often in creams, serums, or patches. Copper peptides (GHK-Cu) and cosmetic peptides (SNAP-8, Matrixyl) are common topical formulations. Skin penetration is limited for most peptides without penetration enhancers.

Delivery of a substance through the skin into systemic circulation, typically via patches or specialized creams. Peptides generally have poor transdermal absorption due to their size, though emerging technologies like microneedle patches aim to overcome this.

The practice of gradually adjusting a dose — typically starting low and increasing slowly to find the optimal dose while minimizing side effects.

A rapid and acute decrease in response to a drug after repeated doses in a short time period. Distinct from slower desensitization, tachyphylaxis can occur after just a few doses. Melanotan II and some GHRPs are susceptible to tachyphylaxis without proper cycling.

An enzyme that maintains telomere length, associated with cellular aging. Epithalon is studied for its potential to activate telomerase, with evidence from human cell culture studies (Khavinson et al., 2003), rodent models, and Russian clinical reports — though no Western randomized controlled trials have been published.

Independent laboratory analysis of a peptide product by an entity not affiliated with the manufacturer or seller. Considered more trustworthy than in-house testing. Reputable peptide suppliers provide third-party COAs.

Australia's regulatory body for therapeutic goods including pharmaceuticals. Classifies peptides under scheduling categories (S4, S8) and regulates personal importation.

The range of drug dosages between the minimum effective dose and the dose that produces unacceptable toxicity. Narrow therapeutic windows require careful dose monitoring.

An independent organization that sets quality standards for medicines, dietary supplements, and food ingredients in the United States. USP-grade ingredients meet published purity and quality standards. Compounding pharmacies often reference USP chapters (e.g., USP <797> for sterile compounding).

A small glass or plastic container used to store lyophilized or reconstituted peptides. Typically sealed with a rubber stopper and aluminum crimp cap.

The international organization responsible for promoting, coordinating, and monitoring anti-doping in sports. Many research peptides are on the WADA prohibited list.

The time required for a drug to be eliminated from the body after discontinuation, typically 5 half-lives. Important when switching between peptides or before medical procedures.